Pro Variant of TP53 Arg72Pro Contributes to Gastric Cancer Risk in Asians: Evidence from a Meta-analysis

  • Su, Xiu-Li (Department of Digestive Diseases, the First Affiliated Hospital of Henan University of Science and Technology) ;
  • Jin, Jian-Jun (Department of Digestive Diseases, the First Affiliated Hospital of Henan University of Science and Technology)
  • Published : 2012.03.31


Background: Previous studies investigating the association between TP53 Arg72Pro polymorphism and gastric cancer (GC) risk in Asian population have reported controversial results. Thus, a meta-analysis was performed. Methods: A comprehensive literature search was conducted and 17 case-control studies were finally included, involving a total of 5,990 GC cases and 6,812 controls. Subgroup analyses were performed by the sample size. Results: Meta-analysis of all 17 studies showed variant genotypes of TP53 Arg72Pro to be associated with an elevated GC risk in three genetic comparison models ($OR_{Pro\;vs.\;Arg}$=1.13, 95%CI 1.03-1.25, $P_{OR}$=0.01; $OR_{Homozygote\;comparison\;model}$=1.33, 95%CI 1.07-1.64, $P_{OR}$=0.009; $OR_{Dominant\;genetic\;model}$=1.13, 95%CI 1.05-1.22, $P_{OR}$=0.002). Besides, a more obvious association was observed after the heterogeneity was decreased (all P values less than 0.001). This association was further identified by both subgroup and sensitivity analyses. Conclusions: This meta-analysis suggests the Pro variant of TP53 Arg72Pro contributes to gastric cancer risk in Asians.


  1. Cao YY, Ge H, Chen LQ, et al (2007). Correlation of 53BP1 and p53 polymorphisms to susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma. Ai Zheng, 26, 1052-7.
  2. Chipuk JE, Bouchier-Hayes L, Kuwana T, et al (2005). PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science, 309, 1732-5.
  3. Chung WC, Lee KM, Lee BI, et al (2006). P53 genetic polymorphism of gastric cancer in Korea. Korean J Intern Med, 21, 28-32.
  4. Cochran WG (1954). The combination of estimates from different experiments. Biometrics, 10, 101-29.
  5. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
  6. Dumont P, Leu JI, Della Pietra AC, 3rd, et al (2003). The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet, 33, 357-65.
  7. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.
  8. Fukase K, Kato M, Kikuchi S, et al (2008). Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet, 372, 392-7.
  9. Galbraith RF (1988). A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med, 7, 889-94.
  10. Gao L, Nieters A, Brenner H (2009). Cell proliferation-related genetic polymorphisms and gastric cancer risk: systematic review and meta-analysis. Eur J Hum Genet, 17, 1658-67.
  11. Hamajima N, Matsuo K, Suzuki T, et al (2002). No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. Cancer Lett, 181, 81-5.
  12. Hartgrink HH, Jansen EP, van Grieken NC, et al (2009). Gastric cancer. Lancet, 374, 477-90.
  13. Higgins J, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58.
  14. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.
  15. Hiyama T, Tanaka S, Kitadai Y, et al (2002). p53 Codon 72 polymorphism in gastric cancer susceptibility in patients with Helicobacter pylori-associated chronic gastritis. Int J Cancer, 100, 304-8.
  16. Huang ZH, Hua D, Du X (2009). Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. Cancer Chemother Pharmacol, 64, 1001-7.
  17. Ihsan R, Devi TR, Yadav DS, et al (2011). Investigation on the role of p53 codon 72 polymorphism and interactions with tobacco, betel quid, and alcohol in susceptibility to cancers in a high-risk population from North East India. DNA Cell Biol, 30, 163-71.
  18. Ioannidis JP, Boffetta P, Little J, et al (2008). Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol, 37, 120-32.
  19. Ioannidis JP, Patsopoulos NA, Evangelou E (2007). Uncertainty in heterogeneity estimates in meta-analyses. BMJ, 335, 914-6.
  20. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
  21. Jiang Y, Ajani JA (2010). Multidisciplinary management of gastric cancer. Curr Opin Gastroenterol, 26, 640-6.
  22. Ke-Xiang Z, Yu-Min L, Xun L, et al (2012). Study on the association of p53 codon 72 polymorphisms with risk of gastric cancer in high incidence Hexi area of Gansu Province in China. Mol Biol Rep, 39, 723-8.
  23. Kim JG, Sohn SK, Chae YS, et al (2009). TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin. Cancer Chemother Pharmacol, 64, 355-60.
  24. Kim JM, Lee OY, Lee CG, et al (2007). p53 Codon 72 and 16- bp duplication polymorphisms of gastric cancer in Koreans. Korean J Gastroenterol, 50, 292-8.
  25. Kim N, Cho SI, Lee HS, et al (2010). The discrepancy between genetic polymorphism of p53 codon 72 and the expression of p53 protein in Helicobacter pylori-associated gastric cancer in Korea. Dig Dis Sci, 55, 101-10.
  26. Lai KC, Chen WC, Jeng LB, et al (2005). Association of genetic polymorphisms of MK, IL-4, p16, p21, p53 genes and human gastric cancer in Taiwan. Eur J Surg Oncol, 31, 1135-40.
  27. Lai KC, Chen WC, Tsai FJ, et al (2005). Arginine and proline alleles of the p53 gene are associated with different locations of gastric cancer. Hepatogastroenterology, 52, 944-8.
  28. Li XZ, Guan LX, Gao L, et al (2004). P53 codon 72 polymorphism and gastric cancer risk in Chinese. Shijie Huaren Xiao Hua Za Zhi, 12, 1955-7.
  29. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  30. Mojtahedi Z, Haghshenas MR, Hosseini SV, Fattahi MJ, Ghaderi A (2010). p 53 codon 72 polymorphism in stomach and colorectal adenocarcinomas in Iranian patients. Indian J Cancer, 47, 31-4.
  31. Mu LN, Lu QY, Yu SZ, et al (2005). Green tea drinking and multigenetic index on the risk of stomach cancer in a Chinese population. Int J Cancer, 116, 972-83.
  32. Resende C, Ristimaki A, Machado JC (2010). Genetic and epigenetic alteration in gastric carcinogenesis. Helicobacter, 15, S34-9.
  33. Riley T, Sontag E, Chen P, et al (2008). Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol, 9, 402-12.
  34. Shen H, Solari A, Wang X, et al (2004). P53 codon 72 polymorphism and risk of gastric cancer in a Chinese population. Oncol Rep, 11, 1115-20.
  35. Shirai O, Ohmiya N, Taguchi A, et al (2010). P53, p21, and p73 gene polymorphisms in gastric carcinoma. Hepatogastroenterology, 57, 1595-601.
  36. Song HR, Kweon SS, Kim HN, et al (2011). p53 codon 72 polymorphism in patients with gastric and colorectal cancer in a Korean population. Gastric Cancer, 14, 242-8.
  37. Stroup DF, Berlin JA, Morton SC, et al (2000). Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA, 283, 2008-12.
  38. Stuck AE, Rubenstein LZ, Wieland D (1998). Bias in metaanalysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ, 316, 469; author reply 70-1.
  39. Vogelstein B, Kinzler KW (2004). Cancer genes and the pathways they control. Nat Med, 10, 789-99.
  40. Vousden KH, Lane DP (2007). p53 in health and disease. Nat Rev Mol Cell Biol, 8, 275-83.
  41. Whibley C, Pharoah PD, Hollstein M (2009). p53 polymorphisms: cancer implications. Nat Rev Cancer, 9, 95-107.
  42. Wroblewski LE, Peek RM, Jr., Wilson KT (2010). Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev, 23, 713-39.
  43. Wu MT, Chen MC, Wu DC (2004). Influences of lifestyle habits and p53 codon 72 and p21 codon 31 polymorphisms on gastric cancer risk in Taiwan. Cancer Lett, 205, 61-8.
  44. Xi YG, Ding KY, Su XL, et al (2004). p53 polymorphism and p21WAF1/CIP1 haplotype in the intestinal gastric cancer and the precancerous lesions. Carcinogenesis, 25, 2201-6.
  45. Yang M, Guo Y, Zhang X, et al (2007). Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis, 28, 1996-2001.
  46. Yi SY, Lee WJ (2006). A p53 genetic polymorphism of gastric cancer: difference between early gastric cancer and advanced gastric cancer. World J Gastroenterol, 12, 6536-9.
  47. Zhang WH, Liu YH, Guo FX, et al (2010). P53 codon 72 polymorphism and risk of gastric cancer in Xibei Chinese population. Wei Sheng Zhi Ye Jiao Yu, 28, 100-1.
  48. Zhou Y, Li N, Zhuang W, et al (2007). P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer, 121, 1481-6.
  49. Zhou Y, Li N, Zhuang W, et al (2010). p53 Codon 72 polymorphism and gastric cancer risk in a Chinese Han population. Genet Test Mol Biomarkers, 14, 829-33.
  50. Zhu KX, li YM, Li X, et al (2009). Association of P53 Arg72Pro polymorphism and Helicobacter pylori infection with risk of gastric cancer in a high incidence area in China. Shijie Huaren Xiao Hua Za Zhi, 17, 3734-9.

Cited by

  1. Genetic association of single nucleotide polymorphisms in P53 pathway with gastric cancer risk in a Chinese Han population vol.32, pp.1, 2015,